BCL2 and myelodysplastic syndrome: Their findings demonstrated that miR-192-5p directly targets the BCL2 promoter, with reduced BCL2 expression observed in MDS patients who respond to therapy, suggesting a suppressive role for miR-192-5p that may inhibit cellular proliferation in this subgroup.